Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lite Strategy, Inc. (LITS : NSDQ)

• Company Description    MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego. Number of Employees: 4

• Price / Volume Information    Yesterday's Closing Price: $0.99 Daily Weekly Monthly 20 Day Moving Average: 178,146 shares Shares Outstanding: 34.03 (millions) Market Capitalization: $33.63 (millions) Beta: 0.21 52 Week High: $6.88 52 Week Low: $0.69 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 20.95% 20.06% 12 Week -14.05% -16.41% Year To Date -25.12% -30.57%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9920 Pacific Heights Blvd. Suite 150 - SAN DIEGO,CA 92121 USA ph: 858-369-7100 fax: 302-655-5049 investor@litestrategy.com https://litestrategy.com

• General Corporate Information    Officers Justin J. File - Chief Executive Officer; Chief Financial Officer a Thomas C. Reynolds - Director Nicholas R. Glover - Director James Flynn - Director Frederick W. Driscoll - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 55279B301 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/26 Next Expected EPS Date: 09/25/26 Share - Related Items Shares Outstanding: 34.03 Most Recent Split Date: 4.00 (0.05:1) Beta: 0.21 Market Capitalization: $33.63 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/25/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.63 Price/Cash Flow: 0.16 Price / Sales: - EPS Growth vs. Year Ago Period: -69.23% vs. Previous Quarter: 19.51% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -90.81 12/31/25 - -68.86 ROA 06/30/26 - - 03/31/26 - -89.33 12/31/25 - -67.48 Current Ratio 06/30/26 - - 03/31/26 - 11.53 12/31/25 - 10.04 Quick Ratio 06/30/26 - - 03/31/26 - 11.53 12/31/25 - 10.04 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 1.56 12/31/25 - 2.23 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©